A two-phases study will be carried out with the following aims 1. st phase (2018-2020) * To investigate the vaccination coverage for Rotavirus vaccine (RV) in Campania Region together with other pediatric vaccinations scheduled in the first 12 months of life: hexavalent, pneumococcal conjugate (PCV), meningococcal B (MenB) * To collect data on appropriate timing of the 3 doses of human bovine pentavalent reassortant vaccine (RV5) administration * To evaluate the frequency of a co-administration of RV5 with other vaccines scheduled in the first 12 months of life (hexavalent/PCV+RV5, MenB+RV5 vs RV5 alone) and assess the variability in co-administration rates according to RV5 dose 2. nd phase (2020-2022) * To investigate the effect of Coronavirus-Disease-19 (COVID-19) pandemic on vaccination coverage in the first year of life, focusing on RV vaccination * To investigate the effect of COVID-19 pandemic on timing of vaccine administration in the first year of life, focusing on those vaccines without catch-up vaccination schedule (i.e. RV) Hypothesis are the following: * Vaccination coverage and timing of vaccines scheduled in the first year of life are not fully aligned with what is established by the Italian National Prevention Plan 2017-2019 * Co-administration of RV5 and MenB in comparison with other coadministration e.g. hexavalent/PCV is lower * Co-administration of RV5 and MenB allows to ensure appropriate timing of RV vaccination schedule * COVID-19 pandemic may have affected the overall vaccination coverage as well as the timing of selected vaccination scheduled in the first year of life, with a more relevant impact on vaccines for whom a catch-up vaccination schedule is not feasible, such as RV immunization.
Age range
6 Weeks – 12 Months
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Overall proportion of children fully immunized for RV and proportion of immunized children in each subgroup
Timeframe: 32 weeks
Proportion of children receiving the first RV5 dose within 12 weeks of age
Timeframe: 32 weeks
Proportion of children completing RV5 schedule within 32 weeks of age
Timeframe: 32 weeks
Proportion of children receiving the co-administration RV5 + MenB
Timeframe: 32 weeks